ArticleOncoscience2015
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.
Naoko Arichi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
14 papers cite it
this papercites it
ArticleOncoscience2015
Naoko Arichi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.